WIPO logo
모바일 | Deutsch | English | Español | Français | 日本語 | Português | Русский | 中文 | العربية |
PATENTSCOPE

국제 및 국내 특허문헌 검색
World Intellectual Property Organization
검색
 
열람
 
번역
 
옵션
 
뉴스
 
로그인
 
도움말
 
기계 번역
1. (WO2006012374) SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE
국제사무국에 기록된 최신 서지정보   

공개번호: WO/2006/012374 국제출원번호: PCT/US2005/025800
공개일: 02.02.2006 국제출원일: 20.07.2005
IPC:
C07D 401/12 (2006.01) ,C07D 413/14 (2006.01) ,C07D 401/14 (2006.01) ,C07D 405/12 (2006.01) ,C07D 405/14 (2006.01) ,C07D 217/02 (2006.01) ,C07D 403/12 (2006.01) ,C07D 417/14 (2006.01) ,C07D 471/04 (2006.01) ,A61K 31/443 (2006.01) ,A61K 31/4427 (2006.01) ,A61K 31/4439 (2006.01) ,A61K 31/444 (2006.01) ,A61K 31/4725 (2006.01) ,A61P 35/00 (2006.01)
출원인: YUAN, Chester Chenguang[US/US]; US (UsOnly)
YANG, Kevin[US/US]; US (UsOnly)
VANDERPLAS, Simon[NL/CA]; CA (UsOnly)
RIAHI, Babak[US/US]; US (UsOnly)
POTASHMAN, Michele[US/US]; US (UsOnly)
PATEL, Vinod F.[US/US]; US (UsOnly)
NOMAK, Rana[TR/TR]; TR (UsOnly)
LI, Aiwen[CN/US]; US (UsOnly)
HUANG, Qi[CN/US]; US (UsOnly)
HARMANGE, Jean-Christophe[FR/US]; US (UsOnly)
ASKEW, JR., Benny C.[US/US]; US (UsOnly)
AMGEN INC.[US/US]; M/S 28-2-C One Amgen Center Drive Thousand Oaks, CA 91320-1799, US (AllExceptUS)
발명자: YUAN, Chester Chenguang; US
YANG, Kevin; US
VANDERPLAS, Simon; CA
RIAHI, Babak; US
POTASHMAN, Michele; US
PATEL, Vinod F.; US
NOMAK, Rana; TR
LI, Aiwen; US
HUANG, Qi; US
HARMANGE, Jean-Christophe; US
ASKEW, JR., Benny C.; US
우선권 정보:
11/185,55619.07.2005US
60/590,54422.07.2004US
발명의 명칭: (EN) SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE
(FR) DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
요약서:
(EN) The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.
(FR) La présente invention concerne des classes de composés, incluant leurs dérivés pharmaceutiquement acceptables, utiles pour traiter l'angiogenèse et les maladies associées telles que le cancer. Les formules I et II dans lesquelles R est un hétérocycle à 9 ou 10 éléments choisi à partir de 7-isoquinolinyle, 2-méthyl-3-oxo-2,3-dihydroindazol-6-yle, [1,6]-naphthydrin-3-yle, [1,7]-naphthydrin-2-yle, 1-oxo-2,3-dihydrobenzofuran-4-yle, 3-oxo-2,3-dihydrobenzofuran-5-yle, dihydro-benzodioxinyle, 6-quinazolinyle, 2-amino-6-quinazolinyle, 4-méthylamino-6-quinazolinyle, 2,4-diamino-6 quinazolinyle, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yle, 2,2-difluoro-l,3-benzodioxol-5-yle et 2,2,3,3 tétrafluoro-2,3-dihydro-l,4-benzodioxin-6-yle, chacun d'eux est facultativement substitué avec un ou plusieurs substituants choisis parmi halo, haloalkyle, C1-6 alkyle, C2-8 alcényle, C2-8 alkynyle, N-diméthylamino-C1-6-alkyle, N-diméthylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyle, amino-sulfonyle, oxazolyle, pyrrolyle,4 morpholinyle, carboxyle, cyano, et acétyle; où R' dans la formule I est choisi parmi un phényle substitué ou non substitué, un hétéroaryle à 5-6 éléments, un hétérocycle bicyclique à 9-10 éléments et un hétérocycle tricyclique à 11-14 éléments, et R' dans la formule II est choisi à partir d'hétérocycles bicycliques spécifiques.
지정국: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
유라시아 특허청 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
유럽 특허청(EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
공개언어: 영어 (EN)
출원언어: 영어 (EN)